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ORAL VALGANCICLOVIR IS SAFE AND EFFECTIVE AS PREEMPTIVE
THERAPY FOR CMV INFECTION IN ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Ayala, E., Greene, J., Sandin, R., Perkins, J., Field, T., Tate, C.,
Goldstein, S.C., Lee H. Mofﬁtt Cancer Center & Research Institute,
Tampa, FL
Despite signiﬁcant advances in prevention and therapy CMV infec-
tion continues to be an important cause of morbidity and mortality in
the hematopoietic stem cell transplant (HSCT) recipient. The stan-
dard drug for preemptive therapy of CMV is intravenous ganciclovir
(GCV). Valganciclovir (VGC), the oral prodrug of GCV has excellent
bioavailability and is ideal for oral therapy. Since March/2002, VGC
was adopted in our center for outpatient preemptive therapy in all
allogeneic HSCT recipients who develop a positive assay for CMV
based on Digene®Hybrid Capture performed as weekly surveillance.
Material and methods: A retrospective review of all patients who
received Valganciclovir as preemptive therapy for CMV infection
between March 1/2002 and May 31/2003 was performed. All patients
had at least 100 days of post-transplant follow up. Patients with a
positive CMV assay were treated with VGC 900 mg PO BID  14
days followed by 900 mg PO QD  7 days. Results: 52 allogeneic
HSCT recipients were followed weekly via Digene hybrid capture
assay. 18 patients (14 Allo, 4 MUD) had 30 episodes of CMV DNA
detection (10 patients had 1 episode, 6 patients had 2 episodes and 2
patients had 3 or more). The rate of response (conversion from
positive to negative in the next 2 weeks after VGC was started) was
93% (28/30). Two patients failed oral VGC. The ﬁrst one with a
severe mucositis became negative with IV GCV. The second one
subsequently failed GCV and became negative in Foscarnet. During
the period of the study one case of CMV enteritis was diagnosed in a
patient with acute GVHD. This patient recovered with GCV. In 2
patients treatment was changed to GCV after one week due to nausea
and vomiting in the setting of acute GVHD. Median duration of
therapy was 21 days (range 10 to 21 days). 66% (20/30) episodes were
associated with acute or chronic GVHD. The mean WBC the day
VGC started was 6.5 109/L (range 1.9-14.5) and decreased to 3.1
109/L (range 0.5-13.9) at the end of the treatment. Minor changes
were noticed in Hb and platelet count. Creatinine remained stable in
all patients. Conclusion: Preemptive therapy of CMV infection with
oral VGC is safe and effective in allogeneic HSCT recipients.
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PALIFERMIN REDUCES SEVERE ORAL MUCOSITIS (OM), IMPROVES
PATIENT QUALITY OF LIFE, AND REDUCES HEALTH RESOURCE USE IN
PATIENTS WITH HEMATOLOGIC MALIGNANCIES RECEIVING HIGH-
DOSE CHEMOTHERAPY (HDCT) AND TOTAL BODY IRRADIATION (TBI)
WITH AUTOLOGOUS PERIPHERAL BLOOD STEM CELL (PBSC) SUP-
PORT: RESULTS FROM A PHASE III TRIAL
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Palifermin (recombinant human keratinocyte growth factor) can
protect and heal the epithelial tissues lining the mouth and gut from
damage caused by anticancer therapy. In animal models, palifermin
reduces chemotherapy and/or radiation-induced injury to the mucosal
lining of the oral cavity and lower gastrointestinal tract. Patients with
hematologic malignancies undergoing HDCT and/or TBI with
PBSC support frequently experience severe OM. OM has been re-
ported by transplant recipients as the most debilitating side effect of
their treatment (Bellm et al, Support Care Cancer, 2000). OM and its
clinical sequelae are also associated with signiﬁcant economic burden
(Sonis et al, JCO, 2001). A phase 3 double-blinded study of palifermin
was conducted in 212 patients with hematologic malignancies under-
going TBI (12 Gy) and HDCT (60 mg/kg etoposide and 100 mg/kg
cyclophosphamide) with autologous PBSC. Patients were randomized
(1:1) to placebo or palifermin 60 g/kg/day for 3 consecutive days
before TBI and 3 consecutive days after PBSC transplant.Measures of
OM and patient-related outcomes (PRO), including mouth and
throat soreness (MTS), were assessed daily until OM grades returned
to WHO grade2. PRO was assessed with a mucositis-speciﬁc daily
diary and the Functional Assessment of Cancer Therapy-General
(FACT-G). Palifermin reduced the incidence and duration of WHO
grades 3, 4 OM and reduced clinical sequelae (Table 1); opioid
analgesic use (median mg morphine equivalent palifermin 212 mg vs
placebo 535 mg), and total parenteral nutrition incidence (palifermin
11% vs placebo 40%). Adverse events occurring more frequently in
palifermin patients includedmild skin and oral erythema with/without
edema, and asymptomatic, transient increases in serum amylase and
lipase. Clinical effects were accompanied by statistically signiﬁcant,
clinically meaningful improvements in measures of PRO, including
MTS and functional and physical well-being domains of the
FACT-G. Palifermin produced a 40% reduction vs placebo in
patient-reported limitations related to eating*, talking*, sleeping*,
swallowing*, and drinking* (*p  0.001), and produced signiﬁcant
reductions in measures of resource utilization. We conclude that
palifermin reduces the incidence and duration of severe OM in pa-
tients undergoing autologous PBSC transplant after TBI and chemo-
therapy conditioning, resulting in improved patient quality of life and
reduced resource utilization.
Table.
Placebo
(n  106)
Palifermin
(n  106) P Value
Clinical Results:
% patients with WHO grade
3, 4 OM 98 63 0.001<
% patients with WHO grade
4 OM 62 20 0.001<
Mean (SD) days WHO grade
3, 4 OM 10.4 (6.2) 3.7 (4.1) 0.001<
Patient-related Outcomes:*
FACT-G functional well-
being 12.7 (4.84) 14.4 (4.71) 0.03
FACT-G physical well-being 17.0 (4.13) 18.8 (4.34) 0.009
MTS 1.3 (0.53) 0.7 (0.49) 0.0001
Medical Resource
Utilization:
Mean days inpatient
hospitalization† 17.3 (5.38) 15.3 (5.06) 0.008
Mean days analgesic opioid
use 11.8 (5.7) 6.8 (5.7) 0.0001
Patients with parenteral
feeding (%)‡ 43 11 0.001<
*Mean daily area under the curve score (SD).
†For hospitalizations post-transplant, only patients with inpatient
admissions were included in the analysis (99 placebo and 100
palifermin patients).
‡Due to oral mucositis.
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